-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Biocryst Pharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Biocryst Pharmaceuticals Inc Operating Income (Loss) for the quarter ending September 30, 2024 was $7.69M.
- Biocryst Pharmaceuticals Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$40.7M, a 62.1% increase year-over-year.
- Biocryst Pharmaceuticals Inc annual Operating Income (Loss) for 2023 was -$104M, a 30.1% increase from 2022.
- Biocryst Pharmaceuticals Inc annual Operating Income (Loss) for 2022 was -$148M, a 16.5% increase from 2021.
- Biocryst Pharmaceuticals Inc annual Operating Income (Loss) for 2021 was -$178M, a 1.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)